Actualités Revolution Medicines Inc - RVMD | Actions NASDAQ

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of...

Revolution Medicines to Participate in March 2025 Investor Conferences

REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines Announces Commencement of Public Offering of Common Stock

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma...

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma...

Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a...

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability...

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Encouraging progression-free survival and overall survival profile Safety findings consistent with previously...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Revolution Medicines Inc (RVMD)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

RVMD Actualités

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Revolution Medicines to Participate in March 2025 Investor Conferences

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Revolution Medicines Announces Commencement of Public Offering of Common Stock

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Revolution Medicines Inc (RVMD) Actualités

Revolution Medicines Inc (RVMD)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

RVMD Actualités

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Revolution Medicines to Participate in March 2025 Investor Conferences

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Revolution Medicines Announces Commencement of Public Offering of Common Stock

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités